GW Pharmaceuticals (GW Pharmaceuticals) Debt-to-Equity : 0.06 (As of Mar. 2021)

View and export this data going back to . Start your Free Trial

What is GW Pharmaceuticals Debt-to-Equity?

GW Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $7.0 Mil. GW Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $35.5 Mil. GW Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2021 was $736.4 Mil. GW Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2021 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for GW Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

GWPRF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.06
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of GW Pharmaceuticals was 0.06. The lowest was 0.00. And the median was 0.01.

GWPRF's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs GWPRF: 0.06

GW Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for GW Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals Debt-to-Equity Chart

GW Pharmaceuticals Annual Data

Trend

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Dec19

Dec20

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.06

GW Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.06	0.05	0.06	0.06

Competitive Comparison of GW Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - General subindustry, GW Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GW Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GW Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where GW Pharmaceuticals's Debt-to-Equity falls into.

GW Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

GW Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.212	+	36.425)	/	741.09
	=	0.06

GW Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.963	+	35.533)	/	736.373
	=	0.06

GW Pharmaceuticals (OTCPK:GWPRF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

GW Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (OTCPK:GWPRF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ

Website

http://www.gwpharm.com

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.